Taken together, these data suggest that pristimerin-mediated down-modulation of NF-kB activity may be an important mechanism for the growth inhibitory effects of pristimerin on pancreatic cancer cells. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.